Autolus Therapeutics plc Deferred Revenue
Autolus Therapeutics plc (AUTL) had Deferred Revenue of $4.72 million as of 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2025-05-08
- 2025-03-31: Deferred Revenue $4.72M.
- 2024-12-31: Deferred Revenue $0.00.
| Period end | Deferred Revenue |
|---|---|
| 2025-03-31 | $4.72M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $0.00 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |